Loading
Life sciences · Journal article
Virulence · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Mpox has emerged as a significant public health concern, spreading across continents with the emergence of new variants. Clade IIb, from the recent global outbreak, and the newly identified Clade Ib have shown changes in transmission dynamics and possibly in severity. We developed a New Zealand White rabbit model of Mpox by using a combination of intradermal and intravenous routes of administration. Following infection, the rabbits developed erythematous papular lesions on the skin, which progressed to crust and scab formation by the second week, ultimately leading to healing and seroconversion. Infection with the Clade Ib and IIb.A.2.1 lineages revealed that both Monkeypox virus (MPXV) variants caused skin and testicular lesions, as well as viral excretion from the nasal cavity, skin, and testicular tissue. However, there were no significant differences in disease severity between the two variants. These findings suggest that this rabbit model could be useful for evaluating countermeasures against MPXV.